Prostate News and Research

RSS

New president elected for the Foundation for Informed Medical Decision Making non-profit organization

Michael J. Barry, MD, of Massachusetts General Hospital and Harvard Medical School, has been named the new president of the Foundation for Informed Medical Decision Making, the non-profit organization in Boston that has pioneered the creation and use of high quality audio-visual decision aids to enhance patient involvement in their own medical decisions.

26 Aug 2009

New drug delivery system for delivering nanoparticles into the tissue

Scientists at UC Santa Barbara have discovered a potential new drug delivery system. The finding is a biological mechanism for delivery of nanoparticles into tissue. The results are published in this week's Proceedings of the National Academy of Sciences.

26 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

FDA clears Aperio Technologies to market breast tissue image analysis application

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Administration (FDA) to market the IHC HER2 Breast Tissue Image Analysis application, available through its patented digital pathology platform.

25 Aug 2009

Capital Earnings & Research to launch prostate cancer awareness campaign

What did all the following businessmen have in common?

24 Aug 2009

High serum insulin levels linked with increased risk of prostate cancer

Demetrius Albanes, M.D., of the Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Md., and colleagues investigated the relationship of the level of serum insulin and glucose, as well as surrogate indices of insulin resistance, to the development of prostate cancer.

24 Aug 2009

Cannabis chemicals stop prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer today.

21 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

Researchers develop new ways for splitting dangerous pair of cancer proteins

A research team led by U of T Mississauga scientists has developed a new way to split up a dangerous pair of cancer proteins, a finding that could ultimately lead to chemotherapy that is more effective and has fewer side effects.

21 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.

20 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

19 Aug 2009

Mandatory folic acid fortification may be unnecessary

Persistently present levels of unmetabolized folic acid found in the population indicate that introducing mandatory food fortification may result in an ‘overdosing’ effect. A study of blood donors, new mothers and babies, published in the open access journal BMC Public Health, has found that most already get enough folic acid from voluntarily fortified foods.

17 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Obesity leads to worse prostate cancer in both black and whites equally

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.

13 Aug 2009

Researchers tackle aggressive cancer cells head on

A multi-institutional team of Boston-area researchers has discovered a chemical that works in mice to kill the rare but aggressive cells within breast cancers that have the ability to seed new tumors.

13 Aug 2009

Transcript: President Obama Town Hall meeting in New Hampshire

President Barack Obama continued his press for public support of health reform initiatives at what the White House called a "Health Insurance Reform Town Hall" meeting at Portsmouth High School in Portsmouth, New Hampshire.

12 Aug 2009

Most people overestimate the life-saving benefits of breast and prostate cancer screening

A public survey conducted in Europe found that the vast majority of people overestimate the life-saving benefits of breast and prostate cancer screening, according to a new study published online August 12 in the Journal of the National Cancer Institute.

12 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Prostate News and Research

New president elected for the Foundation for Informed Medical Decision Making non-profit organization

New drug delivery system for delivering nanoparticles into the tissue

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

FDA clears Aperio Technologies to market breast tissue image analysis application

Capital Earnings & Research to launch prostate cancer awareness campaign

High serum insulin levels linked with increased risk of prostate cancer

Cannabis chemicals stop prostate cancer growth

Results of PCF funded study could impact the standard of care for prostate cancer patients

Researchers develop new ways for splitting dangerous pair of cancer proteins

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Mandatory folic acid fortification may be unnecessary

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Obesity leads to worse prostate cancer in both black and whites equally

Researchers tackle aggressive cancer cells head on

Transcript: President Obama Town Hall meeting in New Hampshire

Most people overestimate the life-saving benefits of breast and prostate cancer screening

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News